Observational studyBMJ open respiratory research2026
High prevalence of persistent tuberculosis-related symptoms 6 months after treatment in pulmonary tuberculosis.
Observational study in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe frequency and determinants of persistent symptoms after microbiological cure remain incompletely defined in pulmonary tuberculosis. We aimed to determine the prevalence of persistent tuberculosis-related symptoms 6 months after treatment initiation and identify associated predisposing factors.
methodsWe analysed data from the prospective observational cohort study, enrolling adults treated for pulmonary tuberculosis at three tertiary hospitals in Korea between 2016 and 2018. Demographic, clinical and radiographic data, and symptoms were assessed using a standardised symptom checklist at baseline and at 2-month and 6-month follow-up visits. Symptom persistence was defined as the presence of any tuberculosis-related symptom at the 6-month visit. Multivariable logistic regression analysis was conducted to identify factors associated with persistent symptoms.
resultsAmong 354 participants (61% men, mean age of 58.5±19.4 years), symptom prevalence decreased from 80.2% at baseline to 25.1% at 6 months. Cough (14.4 %) and dyspnoea (7.6 %) were the most common persistent symptoms. Independent predictors of persistent symptoms included foreign nationality (adjusted OR (aOR) 5.586; 95% CI 1.618 to 19.28), chronic lung disease (aOR 5.034; 95% CI 1.995 to 13.26), presence of tuberculosis-related symptoms at 2 months (aOR 3.195; 95% CI 1.833 to 5.685) and bilateral infiltration on chest X-ray (aOR 1.933; 95% CI 1.018 to 3.650) in the multivariate analysis.
conclusionsA significant proportion of patients experience persistent tuberculosis-related symptoms even 6 months after treatment initiation. These findings highlight the need for ongoing clinical assessment and post-treatment care to address residual symptom burden following pulmonary tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.